Table 2.
Ongoing prospective trials of RASi combine with other therapies to fight against cancer
| NCT number | Classified & Design | conditions | Interventions | Status |
|---|---|---|---|---|
| NCT03563248 | RT+CHT+ARB+Targeted therapy; RCT | Pancreatic Cancer | FOLFIRINOX; Losartan | Recruiting |
| Nivolumab; SBRT; Surgery | ||||
| NCT03864042 | ARB+RT; N-RCT (Sequential Assignment) | Advanced Solid Tumors | Losartan: 25 mg (day 1, 7, 14) | Recruiting |
| Metastatic Melanoma | Caffeine: 50 mg (day 1, 7, 14) | |||
| Omeprazole: 20 mg (day 1, 7, 14) | ||||
| Midazolam: 2 mg (day 1, 7, 14) | ||||
| Encorafenib: 450 mg/d | ||||
| Binimetinib: 45 mg/d | ||||
| NCT03951142 | ARB+CHT+TT; RCT | Glioblastoma | Losartan | Recruiting |
| Brain Metastases | ||||
| NCT03900793 | ARB+TT; N-RCT (Sequential Assignment) | Osteosarcoma | Losartan: 12.5~100 mg, escalating dose | Recruiting |
| Sunitinib | ||||
| NCT04092309 | ACEI+ARNI; RCT | Hematopoietic Stem Cell Transplantation Cardiotoxicity | ACEI; Sacubitril-Valsartan | Recruiting |
| NCT03389724 | ACEI+CHT; RCT | Cardiotoxicity | ACEI (Capoten): 0.5 mg/kg/day | Recruiting |
| Acute Myeloid Leukemia in Children | ||||
| Bone tumor | ||||
| NCT04288700 | ACEI+β-receptor blocker; RCT | Infantile hemangioma | Oral propranolol: 2 mg/kg/d | Recruiting |
| Oral Captopril: 0.1~0.3 mg/kg/d | ||||
| intralesional propranolol injection: 1 mg/mL | ||||
| NCT02770378 | ACEI+CHT; Single arm | Glioblastoma | Temozolomide: 20 mg/m2 BSA *2/d | Active, not recruiting |
| Aprepitant: 80 mg/d | ||||
| Minocycline: 50 or 100 mg*2/d | ||||
| Captopril: 25 or 50 mg*2/d | ||||
| NCT02236806 | ACEI+β-receptor blocker; RCT | Breast Cancer | Bisoprolol: 5 mg/d | Recruiting |
| Cardiotoxicit | Ramipril: 5 mg/d | |||
| Placebo: 1 capsule/d | ||||
| NCT03475186 | ACEI+RRT; Single arm | Glioblastoma | Ramipril: 2.5~5/d | Recruiting |
| Radiotherapy; Complications | ||||
| Cognitive Decline | ||||
| Chemoradiation | ||||
| NCT01646437 | ACEI+β-receptor blocker+thiazide; RCT | Cardiovascular Disease | Hydrochlorothiazide: 25 mg/d; Atenolol: 100 mg/d, Ramipril: 10 mg/d; Simvastatin: 40 mg/d; Placebo | Active, not recruiting |
| Fractures | ||||
| Cancers | ||||
| NCT02596126 | ACEI+aspirin; RCT | Myocardial Infarction | Aspirin: 100 mg/d, Atorvastatin 40 mg/d; Ramipril: 2.5 mg, or 5 mg, or 10 mg/d | Recruiting |
| Cardiovascular Disease | ||||
| NCT01968200 | ACEI; RCT | Cancer | Enalapril: 2.5~10 mg/12 h | Active, not recruiting |
RT: radiation therapy; RCT: randomized control therapy; CHT: chemotherapy.